Biomarker Modulation by Alpelisib (BYL719) in Transorally Resectable, HPV-Associated HNSCC: A Phase II Window Trial
Latest Information Update: 22 Apr 2024
At a glance
- Drugs Alpelisib (Primary)
- Indications Head and neck cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 02 Feb 2023 Status changed from recruiting to discontinued.
- 07 Mar 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2026.
- 07 Mar 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2025.